Dias e Silva, D.; Borba, G.B.; Beal, J.R.; Botrus, G.; Osawa, A.; Araújo, S.E.A.; Moura, F.; Guendelmann, R.A.K.; Uson Junior, P.L.S.
Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report. Int. J. Mol. Sci. 2023, 24, 4209.
https://doi.org/10.3390/ijms24044209
AMA Style
Dias e Silva D, Borba GB, Beal JR, Botrus G, Osawa A, Araújo SEA, Moura F, Guendelmann RAK, Uson Junior PLS.
Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report. International Journal of Molecular Sciences. 2023; 24(4):4209.
https://doi.org/10.3390/ijms24044209
Chicago/Turabian Style
Dias e Silva, Douglas, Guilherme Bes Borba, Juliana Rodrigues Beal, Gehan Botrus, Akemi Osawa, Sérgio Eduardo Alonso Araújo, Fernando Moura, Rafael Aliosha Kaliks Guendelmann, and Pedro Luiz Serrano Uson Junior.
2023. "Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report" International Journal of Molecular Sciences 24, no. 4: 4209.
https://doi.org/10.3390/ijms24044209
APA Style
Dias e Silva, D., Borba, G. B., Beal, J. R., Botrus, G., Osawa, A., Araújo, S. E. A., Moura, F., Guendelmann, R. A. K., & Uson Junior, P. L. S.
(2023). Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report. International Journal of Molecular Sciences, 24(4), 4209.
https://doi.org/10.3390/ijms24044209
